Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 66-73

  Turki, Imène ^a   Hammami, Akil ^a   Kharmachi, Habib ^a   Mousli, Mohamed ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Antibody engineering; Foldon; Neutralization; Rabies virus; Trimeric scFv

Indexed keywords

MONOMER; POLYACRYLAMIDE; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBOSPONDIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BACTERIOPHAGE T4; BINDING AFFINITY; BIOENGINEERING; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RABIES VIRUS; STANDARD; VIRUS NEUTRALIZATION; WORLD HEALTH ORGANIZATION;

ANTIBODY ENGINEERING; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FD; FOLDON; FOLDON MOTIF; MAB; MONOCLONAL ANTIBODY; NEUTRALIZATION; RABIES IMMUNOGLOBULIN; RABIES VIRUS; RABIES VIRUS GLYCOPROTEIN; RAPID FLUORESCENT FOCUS INHIBITION TEST.; RFFIT; RIG; RV; RVG; SCFV; SINGLE-CHAIN VARIABLE FRAGMENT; TRIMERIC SCFV;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIGENS, VIRAL; BACTERIOPHAGE T4; CELL LINE; CRICETINAE; GLYCOPROTEINS; IMMUNIZATION, PASSIVE; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRAL ENVELOPE PROTEINS;

EID: 84884945180     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.08.009     Document Type: Article

References (49)

1. Aavula S.M., Nimmagadda S.V., Biradhar N., Sula S., Chandran D., Lingala R., Villuppanoor S.A. Generation and characterization of an scFv directed against site II of rabies glycoprotein. Biotechnol. Res. Int. 2011, 652147.
2. Asano R., Nakayama M., Kawaguchi H., Kubota T., Nakanishi T., Umetsu M., Hayashi H., Katayose Y., Unno M., Kudo T., Kumagai I. Construction and humanization of a functional bispecific EGFR×CD16 diabody using a refolding system. FEBS J. 2012, 279:223-233.
3. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 2002, 13:603-608.
4. Both L., Banyard A.C., van Dolleweerd C., Wright E., Ma J.K., Fooks A.R. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 2013, 31:1553-1559.
5. Coll J.M. The glycoprotein G of rhabdoviruses. Arch. Virol. 1995, 140:827-851.
6. Coulon P., Ternaux J.P., Flamand A., Tuffereau C. An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol. 1998, 72:273-278.
7. Cuesta A.M., Sánchez-Martín D., Sanz L., Bonet J., Compte M., Kremer L., Blanco F.J., Oliva B., Alvarez-Vallina L. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One 2009, 4:e5381.
8. Duan Y., Gu T.J., Jiang C.L., Yuan R.S., Zhang H.F., Hou H.J., Yu X.H., Chen Y., Zhang Y., Wu Y.G., Kong W. A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency. Mol. Immunol. 2012, 51:188-196.
9. Ducancel F., Muller B.H. Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs 2012, 4:445-457.
10. Fan C.Y., Huang C.C., Chiu W.C., Lai C.C., Liou G.G., Li H.C., Chou M.Y. Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. FASEB J. 2008, 22:3795-7804.
11. Fernandes A., Kaundinya J.O., Daftary G., Saxena L., Banerjee S., Pattnaik P. Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2008, 876:109-115.
12. Fields C., O'Connell D., Xiao S., Lee G.U., Billiald P., Muzard J. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nat. Protoc. 2013, 8:1125-1148.
13. Fitzgerald E.A., Cabasso V.J., Smith J.S., Rastogi S.C. A collaborative study on the testing of rabies immune globulin (human) by the mouse neutralization test (MNT) and the rapid fluorescent focus inhibition test (RFFIT). J. Biol. Stand. 1979, 7:67-72.
14. Friguet B., Chaffotte A.L., Djavadi-Ohaniance L., Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 1985, 77:305-319.
15. Hames B.D., Rickwood D. Gel Electrophoresis of Proteins: A Practical Approach 1990, IRL Press at Oxford University Press, Oxford. 2nd ed.
16. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
17. 3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996, 56:3055-3061.
18. Ito T., Iwamoto K., Tsuji I., Tsubouchi H., Omae H., Sato T., Ohba H., Kurokawa T., Taniyama Y., Shintani Y. Trimerization of murine TNF ligand family member LIGHT increases the cytotoxic activity against the FM3A mammary carcinoma cell line. Appl. Microbiol. Biotechnol. 2011, 90:1691-1699.
19. James K., Bell G.T. Human monoclonal antibody production: current status and future prospects. J. Immunol. Methods 1987, 100:5-40.
20. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E.G., Shaw A., Zinsstag J., Meslin F.X. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 2005, 83:360-368.
21. Letarov A.V., Londer Y.Y., Boudko S.P., Mesyanzhinov V.V. The carboxy-terminal domain initiates trimerization of bacteriophage T4 fibritin. Biochemistry 1999, 64:817-823.
22. Li S.L., Liang S.J., Guo N., Wu A.M., Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol. Immunother. 2000, 49:243-252.
23. Motoi Y., Sato K., Hatta H., Morimoto K., Inoue S., Yamada A. Production of rabies neutralizing antibody in hen's eggs using a part of the G protein expressed in Escherichia coli. Vaccine 2005, 23:3026-3032.
24. Mousli M., Turki I., Kharmachi H., Dellagi K. Genetically engineered colorimetric single-chain antibody fusion protein for rapid diagnosis of rabies virus. Dev. Biol. (Basel) 2008, 131:473-481.
25. Mousli M., Turki I., Kharmachi H., Saadi M., Dellagi K. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J. Virol. Methods 2007, 146:246-256.
26. Muller B.H., Lafay F., Demangel C., Perrin P., Tordo N., Flamand A., Lafaye P., Guesdon J.L. Phage-displayed and soluble mouse scFv fragments neutralize rabies virus. J. Virol. Methods 1997, 67:221-233.
27. Muzard J., Bouabdelli M., Zahid M., Ollivier V., Lacapère J.J., Jandrot-Perrus M., Billiald P. Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro. FEBS J. 2009, 276:4207-4222.
28. Ortega C., Herbet A., Richard S., Kersual N., Costa N., Pèlegrin A., Ducancel F., Couraud J.Y., Navarro-Teulon I., Boquet D. High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. J. Immunol. Methods 2012, 387:11-20.
29. Papanikolopoulou K., Forge V., Goeltz P., Mitraki A. Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage T4 fibritin. J. Biol. Chem. 2004, 279:8991-8998.
30. Perrin P. Techniques for the preparation of rabies conjugates. Laboratory Techniques in Rabies 1996, 433-445. World Health Organization, Geneva. 4th ed. F.X. Meslin, M. Kaplan, H. Koprowski (Eds.).
31. Raux H., Coulon P., Lafay F., Flamand A. Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 1995, 210:400-408.
32. Ray K., Embleton M., Jailkhani B., Bhan M., Kumar R. Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin. Exp. Immunol. 2001, 125:94-101.
33. Rupprecht C.E., Gibbons R.V. Clinical practice. Prophylaxis against rabies. N. Engl. J. Med. 2004, 351:2626-2635.
34. Sánchez-Arévalo Lobo V.J., Cuesta A.M., Sanz L., Compte M., García P., Prieto J., Blanco F.J., Alvarez-Vallina L. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int. J. Cancer 2006, 119:455-462.
35. Sanz L., Blanco B., Alvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. 2004, 25:85-91.
36. Schirrmann T., Al-Halabi L., Dübel S., Hust M. Production systems for recombinant antibodies. Front Biosci. 2008, 13:4576-4594.
37. Shawler D.L., Bartholomew R.M., Smith L.M., Dillman R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 135:1530-1535.
38. Sissoëff L., Mousli M., England P., Tuffereau C. Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor. J. Gen. Virol. 2005, 86:2543-2552.
39. Skerra A., Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988, 240:1038-1041.
40. Tao Y., Strelkov S.V., Mesyanzhinov V.V., Rossmann M.G. Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain. Structure 1997, 5:789-798.
41. Thie H., Binius S., Schirrmann T., Hust M., Dübel S. Multimerization domains for antibody phage display and antibody production. New Biotechnol. 2009, 26:314-321.
42. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 2001, 248:47-66.
43. Webber T., Gurung S., Saul J., Baker T., Spatara M., Freyer M., Robinson A.S., Gage M.J. The C-terminus of the P22 tailspike protein acts as an independent oligomerization domain for monomeric proteins. Biochem. J. 2009, 419:595-602.
44. Weisser N.E., Hall J.C. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol. Adv. 2009, 27:502-520.
45. WHO (World Health Organization) Laboratory Techniques in Rabies 1996, World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
46. WHO (World Health Organization) World Health Organization Expert Consultation on Rabies, Eighth Report, WHO Technical Report Ser. 824 1992, World Health Organization, Geneva.
47. WHO (World Health Organization) Expert Consultation on Rabies, First Report, WHO Technical Report Ser. 931 2005, World Health Organization, Geneva.
48. Willuda J., Honegger A., Waibel R., Schubiger P.A., Stahel R., Zangemeister-Wittke U., Plückthun A. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 1999, 59:5758-5767.
49. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 2002, 76:4634-4642.